Can a new drug shrink Hard-to-Treat tumors?

NCT ID NCT07739966

Not yet recruiting Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial is testing an experimental drug called DS-3939a in adults with advanced solid tumors, including a type of lung cancer. The study has two parts: the first checks safety and the best dose, and the second looks at whether the drug, alone or with other cancer treatments, can shrink tumors. The goal is to find a new option for people whose cancer has spread or cannot be removed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DS-3939a, an experimental drug given by IV infusion, tested alone or with pembrolizumab, carboplatin, pemetrexed, or DS-1103a
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors, including non-small cell lung cancer, potentially slowing or shrinking their cancer.
What could go wrong: This is an early-phase trial, so the drug may not work as hoped or may cause significant side effects. The results will need confirmation in larger studies before it becomes available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER METASTATIC NON-SMALL CELL LUNG CANCER SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.